Skip to main content

Table 2 Predictive power of continuous and categorical CTC-counts for therapy response

From: Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

 

Radiographic evaluation

Clinical criteria

CTC-assessment

Interval

Patients (n=)

Odds Ratio

95 % CI

p=

Odds Ratio

95 % CI

p=

Continuous CTC-values

CTC q0 with OR at q4

33

1.0

0.99-1.02

0.53

1.0

0.99-1.04

0.17

CTC q1 with OR at q4

33

1.03

0.99-1.07

0.17

1.1

0.99-1.13

0.06

CTC q4 with OR at q4

33

1.04

1.0-1.09

0.048

1.1

1.03-1.26

0.009

CTC q10 with OR at q10

23

1.02

0.98-1.07

0.28

1.1

1.0-1.23

0.052

Categorical CTC-counts

CTC q0 with OR at q4

33

6.5

0.7-60.5

0.1

8.0

0.86-74.2

0.07

CTC q1 with OR at q4

33

14.9

1.6-142.2

0.02

19.4

2.0-185.7

0.01

CTC q4 with OR at q4

33

18.0

1.9-174.2

0.01

24.0

2.5-233.5

0.006

CTC q10 with OR at q10

23

16.3

1.4-183.1

0.02

5.0

0.82-30.5

0.08

  1. q, cycle of docetaxel; OR, objective response
  2. p values indicate statistical significance
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us